R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 44.25 PLN 2.08% Market Closed
Market Cap: 1B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Intrinsic Value

The intrinsic value of one RVU stock under the Base Case scenario is 39.46 PLN. Compared to the current market price of 44.25 PLN, Ryvu Therapeutics SA is Overvalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RVU Intrinsic Value
39.46 PLN
Overvaluation 11%
Intrinsic Value
Price
R
Worst Case
Base Case
Best Case

Valuation Backtest
Ryvu Therapeutics SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RVU cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RVU?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Ryvu Therapeutics SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Ryvu Therapeutics SA

Provide an overview of the primary business activities
of Ryvu Therapeutics SA.

What unique competitive advantages
does Ryvu Therapeutics SA hold over its rivals?

What risks and challenges
does Ryvu Therapeutics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ryvu Therapeutics SA.

Provide P/S
for Ryvu Therapeutics SA.

Provide P/E
for Ryvu Therapeutics SA.

Provide P/OCF
for Ryvu Therapeutics SA.

Provide P/FCFE
for Ryvu Therapeutics SA.

Provide P/B
for Ryvu Therapeutics SA.

Provide EV/S
for Ryvu Therapeutics SA.

Provide EV/GP
for Ryvu Therapeutics SA.

Provide EV/EBITDA
for Ryvu Therapeutics SA.

Provide EV/EBIT
for Ryvu Therapeutics SA.

Provide EV/OCF
for Ryvu Therapeutics SA.

Provide EV/FCFF
for Ryvu Therapeutics SA.

Provide EV/IC
for Ryvu Therapeutics SA.

Show me price targets
for Ryvu Therapeutics SA made by professional analysts.

What are the Revenue projections
for Ryvu Therapeutics SA?

How accurate were the past Revenue estimates
for Ryvu Therapeutics SA?

What are the Net Income projections
for Ryvu Therapeutics SA?

How accurate were the past Net Income estimates
for Ryvu Therapeutics SA?

What are the EPS projections
for Ryvu Therapeutics SA?

How accurate were the past EPS estimates
for Ryvu Therapeutics SA?

What are the EBIT projections
for Ryvu Therapeutics SA?

How accurate were the past EBIT estimates
for Ryvu Therapeutics SA?

Compare the revenue forecasts
for Ryvu Therapeutics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ryvu Therapeutics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ryvu Therapeutics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ryvu Therapeutics SA compared to its peers.

Compare the P/E ratios
of Ryvu Therapeutics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Ryvu Therapeutics SA with its peers.

Analyze the financial leverage
of Ryvu Therapeutics SA compared to its main competitors.

Show all profitability ratios
for Ryvu Therapeutics SA.

Provide ROE
for Ryvu Therapeutics SA.

Provide ROA
for Ryvu Therapeutics SA.

Provide ROIC
for Ryvu Therapeutics SA.

Provide ROCE
for Ryvu Therapeutics SA.

Provide Gross Margin
for Ryvu Therapeutics SA.

Provide Operating Margin
for Ryvu Therapeutics SA.

Provide Net Margin
for Ryvu Therapeutics SA.

Provide FCF Margin
for Ryvu Therapeutics SA.

Show all solvency ratios
for Ryvu Therapeutics SA.

Provide D/E Ratio
for Ryvu Therapeutics SA.

Provide D/A Ratio
for Ryvu Therapeutics SA.

Provide Interest Coverage Ratio
for Ryvu Therapeutics SA.

Provide Altman Z-Score Ratio
for Ryvu Therapeutics SA.

Provide Quick Ratio
for Ryvu Therapeutics SA.

Provide Current Ratio
for Ryvu Therapeutics SA.

Provide Cash Ratio
for Ryvu Therapeutics SA.

What is the historical Revenue growth
over the last 5 years for Ryvu Therapeutics SA?

What is the historical Net Income growth
over the last 5 years for Ryvu Therapeutics SA?

What is the current Free Cash Flow
of Ryvu Therapeutics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ryvu Therapeutics SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ryvu Therapeutics SA

Current Assets 295.8m
Cash & Short-Term Investments 247.5m
Receivables 33.2m
Other Current Assets 15m
Non-Current Assets 107.4m
Long-Term Investments 23.5m
PP&E 74.2m
Intangibles 7.9m
Other Non-Current Assets 1.9m
Current Liabilities 97.5m
Accounts Payable 28.3m
Accrued Liabilities 11.3m
Other Current Liabilities 57.9m
Non-Current Liabilities 127.9m
Long-Term Debt 80.6m
Other Non-Current Liabilities 47.3m
Efficiency

Earnings Waterfall
Ryvu Therapeutics SA

Revenue
63.6m PLN
Cost of Revenue
-22.7m PLN
Gross Profit
40.9m PLN
Operating Expenses
-145.9m PLN
Operating Income
-104.9m PLN
Other Expenses
790k PLN
Net Income
-104.1m PLN

Free Cash Flow Analysis
Ryvu Therapeutics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RVU Profitability Score
Profitability Due Diligence

Ryvu Therapeutics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Positive 1-Year Revenue Growth
Declining ROE
22/100
Profitability
Score

Ryvu Therapeutics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

RVU Solvency Score
Solvency Due Diligence

Ryvu Therapeutics SA's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
64/100
Solvency
Score

Ryvu Therapeutics SA's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 80.27 PLN with a low forecast of 67.67 PLN and a high forecast of 104.27 PLN.

Lowest
Price Target
67.67 PLN
53% Upside
Average
Price Target
80.27 PLN
81% Upside
Highest
Price Target
104.27 PLN
136% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RVU?

Click here to dive deeper.

Dividends

Ryvu Therapeutics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for RVU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Ryvu Therapeutics SA

Country

Poland

Industry

Life Sciences Tools & Services

Market Cap

1B PLN

Dividend Yield

0%

Description

Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.

Contact

WOJ. MALOPOLSKIE
Krakow
Centrum Badawczo-Rozwojowe Innowacyjnych Lekow, Leona Henryka Sternbacha 2
+48123140200
ryvu.com

IPO

2011-07-14

Employees

186

Officers

Founder, President of the Management Board & CEO
Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.
Executive VP, Chief Scientific Officer & Vice President of the Management Board
Dr. Krzysztof Daniel BrzĂłzka M.B.A., Ph.D.
COO & Member of the Management Board
Dr. Kamil Sitarz M.B.A., Ph.D.
Chief Business Officer & Member of Management Board
Mr. Vatnak Vat-Ho M.B.A.
Chief Medical Officer & Member of Management Board
Dr. Hendrik Nogai M.D.
Human Resources Manager
Ms. Paulina Wolanin

See Also

Discover More
What is the Intrinsic Value of one RVU stock?

The intrinsic value of one RVU stock under the Base Case scenario is 39.46 PLN.

Is RVU stock undervalued or overvalued?

Compared to the current market price of 44.25 PLN, Ryvu Therapeutics SA is Overvalued by 11%.

Back to Top